2017 Section 7 Green Book

187 / 220

3. Hafkamp HC, Manni JJ, Haesevoets A, et al. Marked differences in sur-
vival rate between smokers and nonsmokers with HPV 16-associated ton-
sillar carcinomas. Int J Cancer 2008;122:2656–2664.
4. Sturgis EM, Cinciripini PM. Trends in head and neck cancer incidence in
relation to smoking prevalence: an emerging epidemic of human
papillomavirus-associated cancers? Cancer 2007;110:1429–1435.
5. Parsons JT, Mendenhall WM, Stringer SP, et al. Squamous cell carcinoma
of the oropharynx: surgery, radiation therapy, or both. Cancer 2002;94:
2967–2980.
6. Parsons JT, Mendenhall WM, Million RR, Stringer SP, Cassisi NJ. The
management of primary cancers of the oropharynx: combined treatment or
irradiation alone? Semin Radiat Oncol 1992;2:142–148.
7. [No authors listed]. Induction chemotherapy plus radiation compared with
surgery plus radiation in patients with advanced laryngeal cancer. The
Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J
Med 1991;324:1685–1690.
8. Spaulding MB, Fischer SG, Wolf GT. Tumor response, toxicity, and sur-
vival after neoadjuvant organ-preserving chemotherapy for advanced laryn-
geal carcinoma. The Department of Veterans Affairs Cooperative
Laryngeal Cancer Study Group. J Clin Oncol 1994;12:1592–1599.
9. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy
versus concomitant chemotherapy and radiation therapy for advanced-stage
oropharynx carcinoma. J Natl Cancer Inst 1999;91:2081–2086.
10. Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head
and Neck Oncology and Radiotherapy Group randomized trial comparing
radiotherapy alone with concomitant radiochemotherapy in advanced-stage
oropharynx carcinoma. J Clin Oncol 2004;22:69–76.
11. Machtay M, Moughan J, Trotti A, et al. Factors associated with severe late
toxicity after concurrent chemoradiation for locally advanced head and
neck cancer: an RTOG analysis. J Clin Oncol 2008;26:3582–3589.
12. Huang K, Xia P, Chuang C, et al. Intensity-modulated chemoradiation for
treatment of stage III and IV oropharyngeal carcinoma: the University of
California-San Francisco experience. Cancer 2008;113:497–507.
13. Worden FP, Kumar B, Lee JS, et al. Chemoselection as a strategy for organ
preservation in advanced oropharynx cancer: response and survival positively
associated with HPV16 copy number. J Clin Oncol 2008;26:3138–3146.
14. Rischin D, Young RJ, Fisher R, et al. Prognostic significance of p16INK4A
and human papillomavirus in patients with oropharyngeal cancer treated on
TROG 02.02 phase III trial. J Clin Oncol 2010;28:4142–4148.
15. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of
patients with oropharyngeal cancer. N Engl J Med 2010;363:24–35.
16. May JT, Rao N, Sabater RD, et al. Intensity-modulated radiation therapy as
primary treatment for oropharyngeal squamous cell carcinoma. Head Neck
2013;35:1796–1800.
17. Posner MR, Lorch JH, Goloubeva O, et al. Survival and human papilloma-
virus in oropharynx cancer in TAX 324: a subset analysis from an interna-
tional phase III trial. Ann Oncol 2011;22:1071–1077.
18. Garden AS, Harris J, Trotti A, et al. Long-term results of concomitant boost
radiation plus concurrent cisplatin for advanced head and neck carcinomas:
a phase II trial of the radiation therapy oncology group (RTOG 99-14). Int
J Radiat Oncol Biol Phys 2008;71:1351–1355.
19. Setton J, Caria N, Romanyshyn J, et al. Intensity-modulated radiotherapy
in the treatment of oropharyngeal cancer: an update of the Memorial
Sloan–Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys
2012;82:291–298.
20. Prestwich RJ, Kancherla K, Oksuz DC, et al. A single centre experience
with sequential and concomitant chemoradiotherapy in locally advanced
stage IV tonsillar cancer. Radiat Oncol 2010;5:121.
21. Greven KM, White DR, Browne JD, Williams DW III, McGuirt WF Sr,
D’Agostino RB Jr. Swallowing dysfunction is a common sequelae after che-
moradiation for oropharynx carcinoma. Am J Clin Oncol 2008;31:209–212.
22. Wilson JA, Carding PN, Patterson JM. Dysphagia after nonsurgical head
and neck cancer treatment: patients’ perspectives. Otolaryngol Head Neck
Surg 2011;145:767–771.
23. Best SR, Ha PK, Blanco RG, et al. Factors associated with pharyngoeso-
phageal stricture in patients treated with concurrent chemotherapy and radi-
ation therapy for oropharyngeal squamous cell carcinoma. Head Neck
2011;33:1727–1734.
24. Feng FY, Kim HM, Lyden TH, et al. Intensity-modulated chemoradiother-
apy aiming to reduce dysphagia in patients with oropharyngeal cancer:
clinical and functional results. J Clin Oncol 2010;28:2732–2738.
25. Setton J, Lee NY, Riaz N, et al. A multi-institution pooled analysis of gas-
trostomy tube dependence in patients with oropharyngeal cancer treated
with definitive intensity-modulated radiotherapy. Cancer 2015;121:294–
301.
26. Shiley SG, Hargunani CA, Skoner JM, Holland JM, Wax MK. Swallowing
function after chemoradiation for advanced stage oropharyngeal cancer.
Otolaryngol Head Neck Surg 2006;134:455–459.
27. Haughey BH, Sinha P. Prognostic factors and survival unique to surgically
treated p161 oropharyngeal cancer. Laryngoscope 2012;122 Suppl 2:S13–
S33.
28. Licitra L, Perrone F, Bossi P, et al. High-risk human papillomavirus affects
prognosis in patients with surgically treated oropharyngeal squamous cell
carcinoma. J Clin Oncol 2006;24:5630–5636.
29. Moore EJ, Henstrom DK, Olsen KD, Kasperbauer JL, McGree ME. Trans-
oral resection of tonsillar squamous cell carcinoma. Laryngoscope 2009;
119:508–515.
30. Hurtuk A, Agrawal A, Old M, Teknos TN, Ozer E. Outcomes of transoral
robotic surgery: a preliminary clinical experience. Otolaryngol Head Neck
Surg 2011;145:248–253.
31. Hurtuk AM, Marcinow A, Agrawal A, Old M, Teknos TN, Ozer E. Qual-
ity-of-life outcomes in transoral robotic surgery. Otolaryngol Head Neck
Surg 2012;146:68–73.
32. Weinstein GS, O’Malley BW Jr, Magnuson JS, et al. Transoral robotic sur-
gery: a multicenter study to assess feasibility, safety, and surgical margins.
Laryngoscope 2012;122:1701–1707.
33. NCCN Clinical Practice Guidelines in Oncology. Head and Neck Cancers
version 2.2014. Available at:
. Accessed May 1, 2015.
34. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or
without concomitant chemotherapy for locally advanced head and neck
cancer. N Engl J Med 2004;350:1945–1952.
35. Terrell JE, Ronis DL, Fowler KE, et al. Clinical predictors of quality of life
in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg
2004;130:401–408.
36. Padilla GV, Grant MM. Psychosocial aspects of artificial feeding. Cancer
1985;55(1 Suppl):301–304.
37. Roberge C, Tran M, Massoud C, et al. Quality of life and home enteral
tube feeding: a French prospective study in patients with head and neck or
oesophageal cancer. Br J Cancer 2000;82:263–269.
38. Radhakrishnan R, Solomon M, Satyamoorthy K, Martin LE, Lingen MW.
Tissue microarray – a high-throughput molecular analysis in head and neck
cancer. J Oral Pathol Med 2008;37:166–176.
39. The R project for statistical computing. R: a language and environment for
statistical computing. Available at: Accessed
May 1, 2015.
40. Therneau T, Atkinson B, Ripley B. Rpart: recursive partitioning and regres-
sion trees. R package version 4.1-8. Available at:
. Accessed May 1, 2015.
41. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radio-
therapy and chemotherapy for high-risk squamous-cell carcinoma of the
head and neck. N Engl J Med 2004;350:1937–1944.
KUMAR ET AL.
HEAD & NECK—DOI 10.1002/HED APRIL 2016
167